Annovis Bio (FRA:07X) Total Operating Expense: €35.64 Mil (TTM As of Mar. 2026)


FRA:07X Annovis Bio Inc FRA:07X
32 GF Score
Price €1.69
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Total Operating Expense?

Annovis Bio FRA:07X +2.06% 32 Total Operating Expense is €35.64 Mil as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Annovis Bio's Total Operating Expense for the three months ended in Mar. 2026 was €15.58 Mil. Annovis Bio's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €35.64 Mil.

Annovis Bio Total Operating Expense Related Terms

Annovis Bio Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Annovis Bio's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Total Operating Expense Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 12.83 24.08 41.30 25.49 25.36

Annovis Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.81 5.44 6.34 8.29 15.58
FRA:07X
32GF Score
Annovis Bio Inc FRA:07X
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €35.64 Mil mean?
Annovis Bio (FRA:07X) has a Total Operating Expense of €35.64 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Annovis Bio and its competitors.
Is Annovis Bio's Total Operating Expense too high?
Annovis Bio's current Total Operating Expense is €35.64 Mil. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Total Operating Expense compare to HYFT and EXOZ?
Annovis Bio's Total Operating Expense of €35.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Annovis Bio and its competitors. Annovis Bio's current Total Operating Expense is €35.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Total Operating Expense of €35.64 Mil. The current Total Operating Expense is €35.64 Mil. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Total Operating Expense is €35.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score

Get the complete analysis for FRA:07X

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.69
Price